AIF Downregulation and Its Interaction with STK3 in Renal Cell Carcinoma

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1371/journal.pone.0100824</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:12717469">http://nrs.harvard.edu/urn-3:HUL.InstRepos:12717469</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>

AIF Downregulation and Its Interaction with STK3 in Renal Cell Carcinoma

Shengqiang Xu1,2, Hongjin Wu1, Huan Nie1, Lei Yue1, Huadong Jiang1, Sheng Xiao2*, Yu Li1*

1 School of Life Science and Technology, Harbin Institute of Technology, Harbin, China, 2 Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

Abstract
Apoptosis-inducing factor (AIF) plays a crucial role in caspase-independent programmed cell death by triggering chromatin condensation and DNA fragmentation. Therefore, it might be involved in cell homeostasis and tumor development. In this study, we report significant AIF downregulation in the majority of renal cell carcinomas (RCC). In a group of RCC specimens, 84% (43 out of 51) had AIF downregulation by immunohistochemistry stain. Additional 10 kidney tumors, including an oxophlic adenoma, also had significant AIF downregulation by Northern blot analysis. The mechanisms of the AIF downregulation included both AIF deletion and its promoter methylation. Forced expression of AIF in RCC cell lines induced massive apoptosis. Further analysis revealed that AIF interacted with STK3, a known regulator of apoptosis, and enhanced its phosphorylation at Thr180. These results suggest that AIF downregulation is a common event in kidney tumor development. AIF loss may lead to decreased STK3 activity, defective apoptosis and malignant transformation.

Introduction
Renal cell carcinoma (RCC) accounts for approximately 90% of all kidney malignancies with rising incidence over the last decades [1,2]. Nephrectomy is effective in removing early tumors. However, when metastasis occurs, RCC is very difficult to treat and has poor prognosis. In spite of recent developments in targeted therapy, which significantly extend median survival, most patients still succumb to cancer.

Apoptosis-inducing factor (AIF) was initially identified as a death effector involved in caspase-independent apoptosis pathway [3–5]. Full length AIF is synthesized in cytoplasm as a precursor (67 kDa). When transported into mitochondria, the precursor is processed by cutting the first 34 amino acids and becomes a 62 kDa mature AIF (AIFmit) that acts as an NADH oxidase [6,7]. In normal cell, AIF anchors to the inner mitochondrial membrane and plays a vital function in maintaining mitochondrial structure and respiratory chain. In response to apoptotic stimuli, AIF is cleaved by calpains or cathepsins to yield a 57 kDa truncated form that translocates to the nucleus to induce DNA condensation and large-scale fragmentation in the presence of endonuclease G (EndoG) [8–11]. Recent studies on necroptosis, a regulated type of large-scale fragmentation in the presence of endonuclease G that translocates to the nucleus to induce DNA condensation and DNA fragmentation. Therefore, it might be involved in cell homeostasis and tumor development. In this study, we report significant AIF downregulation in the majority of renal cell carcinomas (RCC). In a group of RCC specimens, 84% (43 out of 51) had AIF downregulation by immunohistochemistry stain. Additional 10 kidney tumors, including an oxophlic adenoma, also had significant AIF downregulation by Northern blot analysis. The mechanisms of the AIF downregulation included both AIF deletion and its promoter methylation. Forced expression of AIF in RCC cell lines induced massive apoptosis. Further analysis revealed that AIF interacted with STK3, a known regulator of apoptosis, and enhanced its phosphorylation at Thr180. These results suggest that AIF downregulation is a common event in kidney tumor development. AIF loss may lead to decreased STK3 activity, defective apoptosis and malignant transformation.

AIF also participates in maintaining the transformed state of colon cancer cells [16]. Serine/threonine-protein kinase 3 (STK3, also called MST2) is a pro-apoptotic cytoplasmic kinase belonging to the Ste-20 kinase family. STK3 and its family member STK4 (MST1) are the core elements of mammalian Hippo pathway that controls cell development, proliferation, apoptosis, and various stress responses. In the Hippo signaling pathway, STK3 can be activated by binding to the adaptor Salvador Homolog 1 (WW45). Activated STK3 can then further activate its downstream kinase, Large Tumor Suppressor Kinase (LATS), which phosphorylates both Yes-Associated Protein (YAP) and Tazazzin (TAZ). Phosphorylation allows YAP and TAZ to be retained by 14-3-3 protein in the cytoplasm, so that they cannot translocate to nucleus to regulate gene transcription [17,18]. STK3 is also involved in several pro-apoptotic processes. Ras association domain-containing protein 1 (RASSF1A) induces apoptosis by both releasing STK3 from Raf1 binding and enhancing STK3 interaction with LATS1 [19]. In the MST-FOXO signaling pathway that mediates oxidative stress-induced neuronal death, STK3/STK4 (MST2/MST1) phosphorylate forkhead box protein O3 (FOXO3) [20]. The phosphorylation of FOXO3 disrupts its interaction with 14–3–3 proteins and promotes FOXO3 translocation to the nucleus. Overexpression of STK3 or STK4 (MST1) induces a caspase-independent morphological change characteristic of apoptosis. These cells are also more sensitive to death receptor-mediated apoptosis than their wild-type counterparts [21]. STK4 activation can also induce H2B phosphorylation and chromatin condensation via a caspase-dependent pathway [22,23]. In addition, multiple apoptotic agents

* Email: sxiao@rics.bwh.harvard.edu (SZ); liyugene@hit.edu.cn (YL)

Competing Interests: The authors have declared that no competing interests exist.

Copyright: © 2014 Xu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was financed by grants from Heilongjiang Province Department of Education in China (http://www.hlje.net/), and LC04C02 Returned Overseas Personnel Fund from Heilongjiang Province Department of Science and Technology (http://www.hljkjt.gov.cn/) and Support from China Scholarship Council (http://www.csc.edu.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Figure 1. Downregulation of AIF in kidney tumors. (A) A northern blot analysis of 19 types of tumors was performed with an AIF-specific cDNA probe. Significant AIF downregulation was detected in various kidney tumors (from top to bottom: RCC, oxyphilic adenoma, RCC, RCC, transitional
cell carcinoma, CCRCC, transitional cell carcinoma, RCC, epithelial nephroblastoma, and cancer of left kidney). Equal RNA loading was verified by hybridization with actin. N, normal tissue; T, tumor tissue. (B) Immunohistochemistry showed AIF downregulation in RCCs. AIF was expressed in normal renal tubule (arrowhead) but not in glomeruli (arrow) (up left panel), and no AIF signals were seen in an RCC (up right panel). AIF expression in a normal kidney with partial adjacent cancer tissue and paired RCC tissue from the same patient are shown on bottom panel. Strong staining of AIF was observed in normal kidney part (lower left panel) compared to very weak staining in cancer part (lower right panel). (C) Western blot analyses of 20 CCRCCs with paired normal tissues showed no expression of AIF or significant AIF downregulation in 17 CCRCCs. Only three cases (#34, #37, #26) didn’t show AIF downregulation. N, normal tissue; C, cancer tissue.

doi:10.1371/journal.pone.0100824.g001

Materials and Methods

Tumor specimens

Renal cell carcinoma tissue specimens including 51 formalin-fixed and paraffin embedded samples, and 37 liquid nitrogen-frozen samples with the paired normal adjacent tissues were obtained from the First Affiliated Hospital, Harbin Medical University from 2005 to 2009. Clinicopathologic data are summarized in Table S1. Tumor types and stages were assigned according to UICC criteria. All the clinical samples were obtained from patients with written informed consent. The usage of patients’ samples was approved by the Medical Ethics and Human Clinical Trial Committee of the First Affiliated Hospital, Harbin Medical University.

Cell culture

Human Embryonic Kidney 293 cells (HEK293) were grown in Dulbecco’s modified Eagle’s medium (Corning Cellgro, USA) supplemented with 10% fetal bovine serum (FBS) (GIBCO, USA) and 200 mM L-glutamine (Sigma, USA). RCC cell lines Caki-1 (HTB-46) and 786-O (CRL-1932) were grown in RPMI 1640 medium (Corning Cellgro, USA) with 10% FBS and 200 mM L-glutamine. All cells were cultured at 37°C in humidified incubator with 5% CO₂.

Table 1. AIF expression in clinical samples of kidney tumors.

<table>
<thead>
<tr>
<th>Feature</th>
<th>n</th>
<th>AIF expression level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>37</td>
<td>37 (100%)</td>
</tr>
<tr>
<td>RCC</td>
<td>51</td>
<td>8 (15.7%)</td>
</tr>
<tr>
<td>CCRCC</td>
<td>45</td>
<td>7 (15.6%)</td>
</tr>
<tr>
<td>Others **</td>
<td>6</td>
<td>1 (16.7%)</td>
</tr>
</tbody>
</table>

**+++: >50% cells stained and brown in tissue; ++: 20–50% cells stained and snuff color in tissue; +: mild to moderate staining of 5–20% cells in tissue; −/+: <5% of cells stained and faint in tissue; −: negative, non-stained cells in tissue; P value between Normal and Tumor group is less than 0.001.

**Others contain 4 papillary RCC, 1 renal oncocytoma and 1 chromophobe RCC.

doi:10.1371/journal.pone.0100824.t001

**Plasmid construction and transfection**

Total RNA was extracted from HEK293 cell using TRIzol reagent (Invitrogen, USA). First strand cDNA was synthesized using cDNA Synthesis Kit (Thermo, USA). AIF transcript variant 1 and STK3 were amplified and cloned into pDNA3.1 (Invitrogen, USA), pGEX-6p-1 (GE Healthcare, USA) or pCMV-FLAG (pCMV-HA was from Clontech, with HA tag replaced by FLAG). Transient transfusions were performed using Lipofectamince-2000 reagent (Invitrogen, USA) according to manufacturer’s protocol.

AIF Northern blot analysis

A tumor tissue array (BD Clontech Cancer Profiling Array II) was hybridized with a p32-labeled AIF cDNA probe, detected by exposing to an X-ray film. p32-labeled ARTv cDNA probe was also hybridized as control. Hybridization and washing conditions were performed according to manufacturer’s protocol.

Immunohistochemistry and Western blot analysis

Tumor sections were heat-treated to retrieve antigen, blocked in 3% BSA in PBST for 30 min and incubated with AIF antibody (Santa Cruz Biotech, sc-55519, USA; 1:2000 dilution in PBST) overnight at 4°C [28]. HRP-goat anti-mouse secondary antibody (1:1000 dilution in PBS) (Santa Cruz, USA) was added for 1 h and detected by diaminobenzidine (Sigma, USA). Cells were counterstained with hematoxylin. Antibody testing is showed on Fig. S1.

For western blot analysis, cryostat sliced frozen tissue were lysed in RIPA buffer with PMSF and protease inhibitor cocktails (Thermo, USA). Crude protein lysates were used for analysis. All the western blot tests were repeated at least three times. Quantity One software was used in the quantification of western blot data.

GST pull-down assay and immunoprecipitation

For GST pull-down assay and immunoprecipitation, cultured cells were harvested using non-denaturing lysis buffer with PMSF.
and protease inhibitor cocktails [29,30]. The following antibodies were used: anti-AIF antibody (Abcam; ab1998), anti-STK3 and phospho-STK3 antibodies (Cell Signaling; #3952 and #3681), anti-V5 tag and anti-FLAG tag antibodies (Abcam; ab27671 and ab45766), anti-Caspase-3 and anti-actin antibodies (Santa Cruz; sc-56046 and sc-1616).

GST and GST-AIF plasmids were transformed into E. coli BL21 (DE3) and cultured at 37°C until OD₆₀₀ reached 1.0. At this point, IPTG was added (final concentration of 0.25 mM) and cells were then cultured at 16°C for 6 h. The GST or GST-AIF fusion proteins were extracted with lysis buffer and sonicated on ice. After centrifugation, the supernatant of E. coli lysates was immobilized onto glutathione-sepharose 4B resin (GE, USA) at 4°C for 2 h. For the GST pull-down assay, the immobilized GST or GST-fusion proteins were incubated with cell lysates at 4°C for 2 h. After being washed for six times, proteins remaining on the sepharose beads were resuspended with SDS sample buffer, resolved with SDS-PAGE and stained by Coomassie Brilliant Blue G-250. All interested bands were analyzed by Mass-spectrometry.

For immunoprecipitation, pcDNA3.1-AIF-V5 or pCMV-Flag-STK3 were transfected into Caki-1 cells separately. Cells were harvested with lysis buffer 12 h later. After pre-clean, cell lysates were incubated overnight with V5 or FLAG antibody. Immune complex were precipitated by adding protein A beads (GE, USA) and detected by western blot. doi:10.1371/journal.pone.0100824.g002

Figure 2. AIF deletion and promoter methylation in kidney tumors. (A) FISH analyses of 2 RCCs showed loss of AIF (red) as compared to a control chromosome X centromere probe (green). (B) Bisulfite sequencing analyses of AIF promoter region in 4 paired male CCRCCs had aberrant methylation patterns including CpA (green), CpT (red) and CpG (blue). Location of each methylation point is noted at the bottom. Height of columns reflects the frequency detected in CCRCCs. (C) Bisulfite sequencing analyses of AIF promoter region in RCC cell line Caki-1. (D & E) Caki-1 cells were treated with demethylation agent 5-aza-dC at 5 μM or vehicle DMSO for various periods of time; and western blot was performed with antibodies to AIF and actin. AIF levels were quantitated by normalization to actin.
AIF in Renal Cell Carcinoma

**A**

**AIF Transfected Caki-1**

- 0h: 1.2%, 4.3%
- 8h: 1.5%, 4.3%
- 10h: 1.5%, 4.3%
- 12h: 1.5%, 4.3%
- 14h: 1.5%, 4.3%
- 16h: 1.5%, 4.3%

**Caki-1**

- Apoptotic percentage (%)
- 0h: 0.0%
- 8h: 0.0%
- 10h: 0.0%
- 12h: 0.0%
- 14h: 0.0%
- 16h: 0.0%

**Mock Transfected Caki-1**

- 0h: 0.0%
- 8h: 0.0%
- 10h: 0.0%
- 12h: 0.0%
- 14h: 0.0%
- 16h: 0.0%

**Annexin V-FITC Intensity**

- **Time (h):** 0h, 8h, 10h, 12h, 14h, 16h
- **Fold:** 1, 2.1, 2.4, 2.8, 3.3
- **Protein:** AIF, Actin

**B**

**AIF Transfected 786-O**

- 0h: 0.0%
- 8h: 0.0%
- 10h: 0.0%
- 12h: 0.0%
- 14h: 0.0%
- 16h: 0.0%

**786-O**

- Apoptotic percentage (%)
- 0h: 0.0%
- 8h: 0.0%
- 10h: 0.0%
- 12h: 0.0%
- 14h: 0.0%
- 16h: 0.0%

**Mock Transfected 786-O**

- 0h: 0.0%
- 8h: 0.0%
- 10h: 0.0%
- 12h: 0.0%
- 14h: 0.0%
- 16h: 0.0%

**Annexin V-FITC Intensity**

- **Time (h):** 0h, 8h, 10h, 12h, 14h, 16h
- **Fold:** 1, 0.9, 1.3, 1.5, 1.8, 2.3
- **Protein:** AIF, Actin

**C**

**DsRed**

- 0h: 0.0%
- 8h: 0.0%
- 10h: 0.0%
- 12h: 0.0%
- 14h: 0.0%
- 16h: 0.0%

**AIF**

- 0h: 0.0%
- 8h: 0.0%
- 10h: 0.0%
- 12h: 0.0%
- 14h: 0.0%
- 16h: 0.0%

**Hoechst**

- 0h: 0.0%
- 8h: 0.0%
- 10h: 0.0%
- 12h: 0.0%
- 14h: 0.0%
- 16h: 0.0%

**Merge**

- 0h: 0.0%
- 8h: 0.0%
- 10h: 0.0%
- 12h: 0.0%
- 14h: 0.0%
- 16h: 0.0%

**DsRed+ pcDNA-AIF**

- 0h: 0.0%
- 8h: 0.0%
- 10h: 0.0%
- 12h: 0.0%
- 14h: 0.0%
- 16h: 0.0%
Fluorescence in situ hybridization (FISH)
Dual-color FISH was performed as described [31]. BAC DNA clone RP3-438D16 (BACPAC Resources Center, USA) containing the entire AIF genome sequence was labeled with rhodamine using BioPrime DNA Labeling System (Life Technologies, USA). Chromosome X centromeric probe (Metasystems, USA) was used as a control probe. Hybridization signals were counted in 100 morphologically intact nuclei for each case using a Leica DMRB fluorescence microscope equipped with a 100 x oil immersion objective. AIF allelic reduction (or deletion) was scored if AIF signals were less than the control centromere probe in a cell. The cutoff value for an AIF deletion established from non-neoplastic kidney tissue for this probe was 5%.

AIF promoter bisulfite-PCR and sequencing
Three pairs of overlapping bisulfite-specific PCR (BSP) primer sets, covering the fragment from −2635 to +860, were designed according to the instructions of Bisulfite Primer Seeker Program (www.zymoresearch.com/tools/bisulfite-primer-seeker). Primer sequences are showed in Table S2. DNA samples were treated with EZ DNA Methylation-Gold Kit (Zymo Research Corp., USA) for bisulfite conversion. PCR were performed with the corresponding primer sets 30 cycles each. PCR products were cloned into pMD18-T Vector (Takara, Japan). Ten clones from each case were selected randomly for sequencing using BigDye Direct Cycle Sequencing Kit (Applied Biosystems, USA). Applied Biosystems 3500 and 3500 Series Data Collection Software were used for DNA sequencing and data analysis.

AIF is down regulated in RCC
A northern blot analysis of 154 tumors and corresponding normal tissues (BD Clontech Cancer Profiling Array II) showed that, among 19 tissue types, AIF is expressed highest in normal kidney. AIF downregulation was detected in various kidney tumors including a benign renal oxyphilic adenoma, RCCs, and transitional cell carcinomas (Fig. 1A). No significant AIF downregulation was detected in the remaining 18 tumor types. We studied AIF protein expression by immunohistochemistry on 51 cases of kidney tumors including 45 clear cell RCC (CCRCC), 4 papillary RCCs, a chromophobe RCC and a renal oncocytoma. Among 51 tumors, 37 cases had matching normal kidney tissue for this probe for this probe. While all normal kidney had strong AIF signals in the convoluted tubules (++ or +++), none or decreased AIF (− or −/−)

AIF interacted with STK3
(A) Immunorecipitation was performed in Caki-1 cells expressing pcDNA3.1-AIF-V5 or pCMV-flag-STK3; Endogenous STK3 co-precipitated with AIF-V5, FLAG-STK3 was pulled down with endogenous AIF. (B) Caki-1 or 786-O cells transfected with pcDNA3.1-AIF were harvested at various time points and western blots were performed with antibodies against AIF, phosphor-STK3, STK3, caspse-3 and actin. Relative folds are noted on each panel. AIF overexpression induced significant increase of STK3 phosphorylation at Thr180.

Statistics
The statistical significance of AIF expression difference between RCC and normal kidney tissues was determined by Student’s T test. A value of p<0.05 was considered statistically significant.

Results
AIF is down regulated in RCC
A northern blot analysis of 154 tumors and corresponding normal tissues (BD Clontech Cancer Profiling Array II) showed that, among 19 tissue types, AIF is expressed highest in normal kidney. AIF downregulation was detected in various kidney tumors including a benign renal oxyphilic adenoma, RCCs, and transitional cell carcinomas (Fig. 1A). No significant AIF downregulation was detected in the remaining 18 tumor types. We studied AIF protein expression by immunohistochemistry on 51 cases of kidney tumors including 45 clear cell RCC (CCRCC), 4 papillary RCCs, a chromophobe RCC and a renal oncocytoma. Among 51 tumors, 37 cases had matching normal kidney tissue specimens. While all normal kidney had strong AIF signals in the convoluted tubules (++ or +++), none or decreased AIF (− or −/−)

Figure 4. AIF interacted with STK3. (A) Immunorecipitation was performed in Caki-1 cells expressing pcDNA3.1-AIF-V5 or pCMV-flag-STK3; Endogenous STK3 co-precipitated with AIF-V5, FLAG-STK3 was pulled down with endogenous AIF. (B) Caki-1 or 786-O cells transfected with pcDNA3.1-AIF were harvested at various time points and western blots were performed with antibodies against AIF, phosphor-STK3, STK3, caspse-3 and actin. Relative folds are noted on each panel. AIF overexpression induced significant increase of STK3 phosphorylation at Thr180.
AIF overexpression induces apoptosis in RCC cells

To study whether forced expression of AIF affects tumor cell growth, pDNA3.1-AIF was transiently transfected into 2 RCC cell lines, Caki-1 and 786-O. As shown in Figure 3A and 3B, AIF overexpression induced massive apoptosis in both Caki-1 and 786-O cells. Indeed, most transfected cells were dead and detached from culture flasks within 24 h after transfection. As determined by immunofluorescence stain, Caki-1 cells overexpressing pDNA3.1-AIF had AIF signals in nuclei, consistent with its role in apoptosis (Fig. 3C).

AIF interacts with STK3 and induces STK3 phosphorylation in RCC cell line

To study the mechanisms of AIF-induced apoptosis in RCC, we performed a GST-AIF pull down assay using Caki-1 cell lysates. Pull down products were separated in a SDS-PAGE gel and proteins were identified by mass spectrometry. One of the AIF-interacting proteins was STK3 (Fig. S3). To confirm this result, pDNA3.1-AIF-V5 was expressed in Caki-1 cells, and immunoprecipitation was performed with anti-V5 antibody. Endogenous STK3 was detected by western blot in the co-precipitation of AIF-V5. A similar study of Caki-1 cells overexpressing FLAG-tagged STK3 showed co-precipitation of STK3-FLAG with endogenous AIF (Fig. 4A).

To study whether AIF expression affects STK3 activation, Caki-1 and 786-O cells were transfected with pDNA3.1-AIF construct. AIF expression increased from 8 h to 14 h after transfection. As AIF increased, a significant increment of STK3 phosphorylation at Thr180 was detected, while the total STK3 did not change. No significant caspase-3 activation was observed during these time points (Fig. 4B).

Discussion

AIF was initially identified as a candidate tumor suppressor because of its role in apoptosis. Upon an apoptotic signal, AIF translocates from mitochondria to nucleus where it triggers caspase-independent programmed cell death. Paradoxically, AIF also plays a role in cell survival. It has been reported that AIF is required to maintain the mitochondrial respiratory complex I. Moreover, AIF is a free radical scavenger that prevents apoptosis induced by reactive oxygen species [15,34]. In fact, the role of AIF on cell death may be cell type-specific. For example, AIF gene silencing protects renal tubular epithelial cells against cisplatin-induced cell death [35]. However, AIF deficient human colon carcinoma cells are more sensitive to peroxide- and drug-induced apoptosis than the wild type counterparts [16]. AIF is predominantly overexpressed in several tumors including colon and squamous cell carcinomas [36,37]. In this study, we reported that AIF expression was considerably higher in normal kidney as compared to the remaining 18 tissue types studied. Furthermore, significant AIF downregulation was detected in most kidney tumors. These studies suggest a tissue-specific role of AIF in tumorigenesis. AIF downregulation was also detected in a case of adenoma, which indicates that AIF downregulation is an early event in kidney tumor development. Our studies show that both genomic deletion and promoter methylation cause AIF downregulation in RCC, although intragenic mutations were not identified.

The profiling of DNA methylation in AIF promoter region using bisulfite sequencing showed a complex pattern including frequent methylcytosines in non-CpG sequences in RCC. Furthermore, Caki-1 cells had a CpT methylation, and demethylation by 5-aza-2cytidine significantly increased AIF expression. Although the functional significance of non-CpG methylation is not completely understood, increasing data have implied the correlations between non-CpG methylation and tissue-specific gene expression. For example, non-CpG methylation is reported to be more prevalent in wild-type murine ES Cells than in tissues [38], and studies of murine NFI gene have revealed non-CpG methylation in the oocyte and the maternally derived allele of the 2-cell embryo [39]. Recently, cytosine hypermethylation was detected in peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) promoter region in diabetic specimens, and the majority of the methylated cytosines were non-CpG methylation. It has also been reported that human myotubes treated with tumor necrosis factor-α (TNF-α) have acute increase of non-CpG methylation level in PGC-1α promoter [40]. These findings

AIF in Renal Cell Carcinoma
suggest non-CpG methylation may carry out complex biological function in cells.

AIF induces DNA fragmentation and chromatin condensation when entering the nucleus. However, the exact mechanisms are not completely understood. It is well accepted that AIF does not possess nuclease activity, and the DNA fragmentation induced by AIF depends on its DNA binding capability. In an in vitro cell-free system, AIF alone is capable of inducing chromatin condensation and DNA loss in the isolated nuclei [41,42]. However, AIF has no effect on preheated nuclei. This evidence suggests that other nuclear factors are involved in AIF-induced chromatin condensation [43]. Three nuclear proteins have been reported to be associated with AIF: Endonuclease G, Cyclophilin A, and H2AX. H2AX is a major component of chromatin and plays a role in assembling DNA repair complex when DNA damage occurs. The interaction between AIF and H2AX is believed to play a role in caspase-independent DNA fragmentation [13]. AIF binds to H2AX only when its ser139 is phosphorylated. Interestingly, STK4, a STK3 family member, is capable of phosphorylating ser139 of H2AX [44]. Our study showed that AIF binds to STK3, leading to increasing STK3 activity. We are currently studying the possibility that AIF-induced STK3 activation phosphorylates H2AX in kidney cells that, in return, binds to AIF to induce apoptosis.

Kidney cancer is one of the most common cancers, and several types of kidney tumors are more common in male. For example, male-to-female ratios for CCRCC, Bellini duct carcinoma and medullary carcinoma are approximately 2:1. Male patients also have higher possibility of metastatic spread and worse prognosis in CCRCC [26]. Interestingly, AIF is located on chromosome X. Whether AIF is capable of escaping chromosome X inaction and whether leaking AIF expression contributes to protection from malignant transformation in female patients are probably worth further evaluation.

In summary, our finding that AIF is frequently downregulated in RCC suggests that loss of AIF may be involved in RCC development. The interaction between AIF and STK3 also reveals a novel role of AIF in regulating programmed cell death. Targeting the AIF signaling pathway therefore may be a viable option for the treatment of RCC patients.

References


